Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Vomiting 4Nausea 4Myeloproliferative Disorders 4Leukemia, Myeloid, Acute 4Sezary Syndrome 3Primary Myelofibrosis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pdgfra-Associated Chronic Eosinophilic Leukemia 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Neutrophilic, Chronic 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Hairy Cell 3Hodgkin Disease 3Burkitt Lymphoma 3Testicular Neoplasms 2Neuroblastoma 2Neoplasms, Plasma Cell 2Myelodysplastic-Myeloproliferative Diseases 2

Interventions

Cyclophosphamide 10fludarabine 8Mycophenolic Acid 7Tacrolimus 6Melphalan 6ruxolitinib 5fludarabine phosphate 5Imatinib Mesylate 5Busulfan 5Bone Marrow Transplantation 5ponatinib 4Mesna 4Azacitidine 4nilotinib 3Whole-Body Irradiation 3Thiotepa 3Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Cyclosporine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3lintuzumab 2Vorinostat 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2Filgrastim 2Alemtuzumab 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Aprepitant × Myeloid × Clear all
NCT00954941 2015-06-25

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 7 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Nausea, Vomiting, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡